Micronized fenofibrate decreases progression of coronary disease in type 2 diabetes

被引：0
|
作者：
Gladstone, PSJ
McLaughlin, PR
Syvanne, M
Steiner, G
机构：
[1] Toronto Gen Hosp, Toronto, ON, Canada
[2] Univ Helsinki, Helsinki, Finland
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1989
引用
收藏
页码：409 / 409
页数：1
相关论文
共 50 条
  • [1] Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:: the Diabetes Atherosclerosis Intervention Study, a randomised study
    Steiner, G
    Hamsten, A
    Hosking, J
    Stewart, D
    McLaughlin, P
    Gladstone, P
    Sole, M
    Syvanne, M
    Hamsten, A
    Camelon, K
    Schloegl, G
    Genest, J
    Reeves, F
    Savard, R
    Letarte, A
    Bellavance, N
    Touchette, J
    Latour, Y
    Marchand, P
    Rondeau, C
    Rivard-Gervais, N
    Belanger, A
    Hamel, D
    Dumas, R
    Sandri, M
    Morin, N
    Caponi, E
    Barbeau, C
    Gauthier, S
    Ooi, TC
    Davies, RF
    Braaten, JT
    Baker, A
    Favreau, C
    Collar, C
    Zinman, B
    Gladstone, P
    Aldridge, H
    Donat, DJ
    Tsui, E
    Barnie, A
    DiMonte, L
    MacLean, S
    Bond, M
    Camelon, K
    Martin, C
    Zawacki, R
    Dziuran, K
    Gouveia, MR
    Taskinen, MR
    LANCET, 2001, 357 (9260): : 905 - 910
  • [2] Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
    Athyros, VG
    Papageorgiou, AA
    Athyrou, VV
    Demitriadis, DS
    Kontopoulos, AG
    DIABETES CARE, 2002, 25 (07) : 1198 - 1202
  • [3] Effect of micronized fenofibrate on microvascular complications of type 2 diabetes: a systematic review
    Czupryniak, Leszek
    Joshi, Shashank R.
    Gogtay, Jaideep A.
    Lopez, Meena
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (11) : 1463 - 1473
  • [4] Effect of Fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes Mellitus
    Genest, J
    Frohlich, J
    Steiner, G
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (07): : 848 - 853
  • [5] Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes
    Grieve, Stuart M.
    Ansquer, Jean-Claude
    Keech, Anthony C.
    FUTURE CARDIOLOGY, 2006, 2 (06) : 635 - 646
  • [6] FENOFIBRATE USE AND INCIDENCE AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES
    Frazier, Rebecca
    Mehta, Rupal
    Cai, Xuan
    Lee, Jungwha
    Scialla, Julia
    Susztak, Katalin
    Isakova, Tamara
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (04) : 538 - 538
  • [7] Atorvastatin and micronized fenofibrate, alone and in combination, in type-2 diabetes mellitus with combined hyperlipidemia
    Athyros, V
    Papageorgiou, AA
    Athyrou, VV
    Demitriadis, DS
    Kontopoulos, AG
    EUROPEAN HEART JOURNAL, 2002, 23 : 170 - 170
  • [8] Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes
    Li, Bo
    Luo, Yan-Rong
    Tian, Feng
    Chen, Yun-Dai
    Tian, Jin-Wen
    Ding, Yu
    Zhu, Mei
    Li, Jing-Wei
    Zhang, Ying-Qian
    Shi, Wei-Ming
    ATHEROSCLEROSIS, 2020, 300 : 10 - 18
  • [9] Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?
    Croyal, M.
    Kaabia, Z.
    Leon, L.
    Ramin-Mangata, S.
    Baty, T.
    Fall, F.
    Billon-Crossouard, S.
    Aguesse, A.
    Hollstein, T.
    Sullivan, D. R.
    Nobecourt, E.
    Lambert, G.
    Krempf, M.
    DIABETES & METABOLISM, 2018, 44 (02) : 143 - 149
  • [10] Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients
    Wyatt, Jamison
    Nandish, Shailesh
    Oliveros, Rene
    Zion, Adrienne S.
    Lujan, Michael S.
    Chilton, Robert
    VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 1 - 8
12345